Synopsis
0
CEP/COS
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
API SUPPLIERS
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
Click Us!
NDC
KDMF
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
EU-WC
NDC
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
A Ozenoxacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ozenoxacin, including repackagers and relabelers. The FDA regulates Ozenoxacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ozenoxacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ozenoxacin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ozenoxacin supplier is an individual or a company that provides Ozenoxacin active pharmaceutical ingredient (API) or Ozenoxacin finished formulations upon request. The Ozenoxacin suppliers may include Ozenoxacin API manufacturers, exporters, distributors and traders.
click here to find a list of Ozenoxacin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ozenoxacin DMF (Drug Master File) is a document detailing the whole manufacturing process of Ozenoxacin active pharmaceutical ingredient (API) in detail. Different forms of Ozenoxacin DMFs exist exist since differing nations have different regulations, such as Ozenoxacin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ozenoxacin DMF submitted to regulatory agencies in the US is known as a USDMF. Ozenoxacin USDMF includes data on Ozenoxacin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ozenoxacin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ozenoxacin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ozenoxacin Drug Master File in Japan (Ozenoxacin JDMF) empowers Ozenoxacin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ozenoxacin JDMF during the approval evaluation for pharmaceutical products. At the time of Ozenoxacin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ozenoxacin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ozenoxacin Drug Master File in Korea (Ozenoxacin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ozenoxacin. The MFDS reviews the Ozenoxacin KDMF as part of the drug registration process and uses the information provided in the Ozenoxacin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ozenoxacin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ozenoxacin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ozenoxacin suppliers with KDMF on PharmaCompass.
A Ozenoxacin written confirmation (Ozenoxacin WC) is an official document issued by a regulatory agency to a Ozenoxacin manufacturer, verifying that the manufacturing facility of a Ozenoxacin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ozenoxacin APIs or Ozenoxacin finished pharmaceutical products to another nation, regulatory agencies frequently require a Ozenoxacin WC (written confirmation) as part of the regulatory process.
click here to find a list of Ozenoxacin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ozenoxacin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ozenoxacin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ozenoxacin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ozenoxacin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ozenoxacin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ozenoxacin suppliers with NDC on PharmaCompass.
Ozenoxacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ozenoxacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ozenoxacin GMP manufacturer or Ozenoxacin GMP API supplier for your needs.
A Ozenoxacin CoA (Certificate of Analysis) is a formal document that attests to Ozenoxacin's compliance with Ozenoxacin specifications and serves as a tool for batch-level quality control.
Ozenoxacin CoA mostly includes findings from lab analyses of a specific batch. For each Ozenoxacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ozenoxacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Ozenoxacin EP), Ozenoxacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ozenoxacin USP).
LOOKING FOR A SUPPLIER?
